肿瘤细胞治疗研究
英文原题：Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes.
癌症基因治疗的当前医学现实反映在全球市场上已有十余款获批产品，包括溶瘤病毒及其他病毒载体，以及作为离体基因修饰细胞治疗产品的 CAR T 细胞。
癌症基因治疗的当前医学现实体现为全球市场上已有十余款获批产品，包括溶瘤病毒及其他病毒载体，以及作为离体基因修饰细胞疗法的CAR T细胞。合成抗肿瘤核酸治疗药物的开发一直以较低但稳定的速度推进，其驱动力来自大量替代性核酸平台（从各种反义寡核苷酸、siRNA、microRNA、lncRNA、sgRNA到较大的mRNA和DNA）以及几类物理和化学递送技术。本综述总结了肿瘤靶向核酸递送的挑战与策略。主要聚焦于作为纳米载体的polyplexes（聚阳离子复合物），阐述了跨越多重屏障进入肿瘤细胞的递送方案。
The current medical reality of cancer gene therapy is reflected by more than ten approved products on the global market, including oncolytic and other viral vectors and CAR T-cells as ex vivo gene-modified cell therapeutics. The development of synthetic antitumoral nucleic acid therapeutics has been proceeding at a lower but steady pace, fueled by a plethora of alternative nucleic acid platforms (from various antisense oligonucleotides, siRNA, microRNA, lncRNA, sgRNA, to larger mRNA and DNA) and several classes of physical and chemical delivery technologies. This review summarizes the challenges and strategies for tumor-targeted nucleic acid delivery. Focusing primarily on polyplexes (polycation complexes) as nanocarriers, delivery options across multiple barriers into tumor cells are illustrated.
MEMBER ACCOUNT
登录成功会直接打开下一页。
